FDA Approves Belantamab in R/R Multiple Myeloma FDA Approves Belantamab in R/R Multiple Myeloma

The first-in-class drug belantamab mafodotin (Blenrep) has been approved in the United States for use in relapsed and refractory multiple myeloma.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news